Injury to the central nervous system (CNS) can leave patients with devastating neurological deficits that may permanently impair independence and diminish quality of life. Recent insights into how the CNS responds to injury and reacts to critically timed interventions are being translated into clinical applications that have the capacity to drastically improve outcomes for patients suffering from permanent neurological deficits due to spinal cord injury, stroke, or other CNS disorders. The translation of such knowledge into practical and impactful treatments involves the strategic collaboration between neurosurgeons, clinicians, therapists, scientists, and industry. Therefore, a common understanding of key neuroscientific principles is crucial. Conceptually, current approaches to CNS revitalization can be divided by scale into macroscopic (systems-circuitry) and microscopic (cellularmolecular). Here we review both emerging and well-established tenets that are being utilized to enhance CNS recovery on both levels, and we explore the role of neurosurgeons in developing therapies moving forward. Key principles include plasticity-driven functional recovery, cellular signaling mechanisms in axonal sprouting, critical timing for recovery after injury, and mechanisms of action underlying cellular replacement strategies. We then discuss integrative approaches aimed at synergizing interventions across scales, and we make recommendations for the basis of future clinical trial design. Ultimately, we argue that strategic modulation of microscopic cellular behavior within a macroscopic framework of functional circuitry re-establishment should provide the foundation for most neural restoration strategies, and the early involvement of neurosurgeons in the process will be crucial to successful clinical translation.
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njury to the central nervous system (CNS) can leave patients with devastating functional deficits that may permanently impair independence and diminish quality of life. From a societal perspective, this remains a huge and ABBREVIATIONS: BMI, brain-machine interface; CNS, central nervous system; CST, corticospinal tract; ECoG, electrocorticography; EES, epidural electrical stimulation; ESS, European Stroke Scale; FES, functional electrical stimulation; GAP43, growth-associated protein 43; MAP, myelinassociated protein; PTEN, phosphatase and tensin; SCI, spinal cord injury; STDP, spike timingdependent plasticity; TMS, transcranial magnetic stimulation costly burden. 1 Although the CNS has some capacity for recovery during the first year after injury, chronic deficits tend to be static and display minimal improvement over time. 2, 3 Recent neuroscientific advances, however, have led to new hope for conditions previously considered untreatable. 4 For example, for the first time in history, novel interventions have allowed patients with chronic and clinically complete spinal cord injuries (SCI) to regain some degree of voluntary motor control of the legs [5] [6] [7] [8] [9] and arms. 10 Furthermore, through combined immunotherapy and task-based rehabilitation protocols, functional corticospinal tract (CST) regeneration 11 and functional synapse formation 12 have been produced in animal models of SCI, while full functional recovery of forelimb activity has been demonstrated in animal models of stroke. 13 Collectively, these advances are based on a set of emerging neuroscience principles that are being translated from the laboratory to the clinic, providing the first tangible evidence of meaningful recovery in such patients. Conceptually, approaches to repairing the CNS can be classified by scale into systems-circuitry level approaches (ie, macroscopic) and cellular-molecular interventions (ie, microscopic). Macroscopic approaches currently under investigation include rehabilitation paradigms 14, 15 with or without neural interfaces 5, 16 and electrical stimulation strategies [6] [7] [8] [9] [10] [17] [18] [19] [20] aimed at increasing the excitability of intact neural elements and inducing circuit plasticity across lesions. Contemporary microscopic strategies, most of which will require surgical administration, include cellular replacement (ie, stem or embryonic cell) therapy, [21] [22] [23] [24] [25] [26] induction of axonal growth via molecular mechanisms, [27] [28] [29] [30] [31] [32] [33] optogenetic modulation, 34 immunotherapy, 13, [35] [36] [37] and/or enhancement of neurotrophic guidance. 38 Emerging evidence suggests that strategically combining approaches on both scales and utilizing conscious intent to re-engage damaged circuitry will be essential to achieving full neurological recovery. 4, 39 In this paper, we review key scientific principles, discuss integrative approaches, and examine the role of neurosurgeons in translating such techniques into clinical realities.
SYSTEMS-CIRCUITRY PRINCIPLES Plasticity Drives Functional Recovery
In the acute-to-subacute period after a CNS injury (ie, several days to several weeks), some level of spontaneous clinical improvement often occurs due to reduction in edema, resolution of diaschisis, and optimization of residual dormant (or recovering) but intact functional elements. 40, 41 Further recovery is achieved through intrinsic plasticity mechanisms such as collateral sprouting from nearby intact neurons and/or dynamic alterations in existing synapses through changes in neurotransmitters, ionic gradients, gap junctions, and glial cells. [42] [43] [44] [45] [46] [47] [48] [49] During this period, axonal and synaptic plasticity are enabled because the extracellular neural environment has relatively loose extracellular space, more neurotrophic factors, additional open synaptic sites, and probing axonal growth cones. 33, 50, 51 Neurogenesis, on the other hand, does not significantly contribute to recovery of function.
52-54 After 6 to 12 mo, further clinical progress wanes 55, 56 as the environment stabilizes by forming a glial scar with inhibitory mechanical properties 57, 58 and re-expresses inhibitory molecules such as myelin-associated proteins (MAPs) and proteoglycans. [59] [60] [61] [62] Interventions aiming to maximize neural recovery, therefore, have tended to focus on the critical time period before 1 yr when functional plasticity mechanisms remain active. 63 Efforts after this period usually emphasize strengthening existing circuits, building endurance, and treating the deleterious effects of inappropriate plasticity (eg, spasticity and seizures). 64 Copyright 1965. More recently, however, emerging evidence suggests that even patients with chronic and complete SCIs may retain some capacity for functional improvements through previously untapped plasticity mechanisms. In 2016, Donati et al 5 demonstrated that some recovery could be achieved in patients with chronic and complete thoracic SCIs by implementing extensive training with a brain-controlled exoskeleton. In doing so, this group provided the first report of a therapeutic strategy that enabled the reclassification of patients from chronic-complete to incomplete SCIs. A similar result was recently published in 2017 by Rejc et al, 9 showing that extensive training combined with epidural electrical stimulation (EES) of spinal elements distal to a lesion could achieve similar long-term results.
The implication of these pilot human experiments is that there are likely surviving but dormant, or subclinical, white matter tracts that are recruitable for strengthening and plasticity induction in select cases. In most SCIs which are usually due to blunt traumatic compression, hemorrhage tends to occur preferentially in the central gray matter due to its softer consistency and relatively increased vascularity (Figure 1 ). 64 Thus, there is potential for some more mechanically resilient peripheral white matter tracts to remain intact (ie, central cord contusions). Importantly, the volume of residual white matter tracts has been shown to directly relate to postinjury locomotive ability in rat models of SCI. 65 In parallel, human SCIs that are clinically complete may also demonstrate residual subclinical supraspinal connections. Such injuries are now being called "discomplete," indicating potential for a clinical response to the aforementioned interventions. 66, 67 As such, exoskeleton and spinal cord stimulation strategies are now being combined to help further facilitate rehabilitation in motor complete, or discomplete, paraplegics. 8 In addition to intrinsic spinal plasticity, the relative role of cortical plasticity in facilitating such recovery is yet undefined. Significant cortical reorganization is known to occur after chronic nonuse or amputation of a limb [68] [69] [70] [71] as well as in response to directly injured motor cortex, 72 and such reorganization tends to include the expansion of somatotopically neighboring functions into newly dormant or damaged areas in a behaviordependent fashion. 72 Furthermore, there is some evidence that this plasticity is reversible. 73, 74 Therefore, it is also likely that re-engagement of previously lost functions can help maintain or induce cortical plasticity to re-establish and/or re-grow critical somatotopy and connectivity for improved performance ( Figure 2 ). 74, 75 Experimental approaches aimed at enhancing cortical plasticity after stroke have included electrical stimulation of the cortex, 18, 76 vagus nerve stimulation, 77 paired associative stimulation (ie, paired peripheral nerve and transcranial magnetic stimulation [TMS]), 78 and brain-state-dependent stimulation (ie, paired TMS and neural interfacing). 79 While cortical stimulation paradigms have shown promise in animal models, 17 ,80,81 a recent phase III clinical trial was negative at its primary endpoints. 19 However, future studies may incorporate a variety of novel stimulation protocols and/or combine stimulation with a host of microscopic interventions discussed later in this review. The lack of an FDA-approved device for this type of stimulation remains a major barrier. However, a fully implantable electrocorticography (ECoG) device with wireless transmission capabilities is now undergoing clinical trials in Europe for brain-machine interface (BMI) applications, but it is currently being used for recording only.
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FIGURE 3. Assistive vs rehabilitative interfaces. The assistive interface bypasses a lesion to produce an action, whereas the rehabilitative interface times a goal-oriented intention with positive feedback to induce plasticity. The effector device can be anything that produces a desired output, including cursor on a screen, an exoskeleton, FES, EES, EMG, or a typing device, for example. Reproduced from Krucoff et al, 2016 4 under license CC BY-ND 4.0.
Neurons that Fire Together Wire Together
Also known as Hebbian plasticity, the principle of spike timingdependent plasticity (STDP) states that synaptic strength is redistributed to favor functionally relevant pathways that are coincidently active. [83] [84] [85] This tenet underlies several new rehabilitation paradigms that utilize neural interfaces and invasive stimulation strategies to pair goal-oriented intention with critically timed feedback to encourage positive plasticity. The paradigm shift from assistive to rehabilitative interfaces has been explored in several recent reviews, 4, 86, 87 and a schematic diagram outlining the conceptual evolution in this approach is reproduced in Figure 3 . The experiments of Donati et al 5 and Rejc et al 9 explored in the previous section also likely owe much of their success to their utilization of STDP principles, as these systems pair conscious intention with exoskeleton and EES-aided movements, respectively. Overlapping principles are also explored in the section "Conscious Engagement is Key for Long-term Functional Improvement," wherein the importance of conscious engagement is discussed.
Intact Neuromuscular Elements Distal to a CNS Lesion can be Recruited for Function
SCI leads to a "disconnection syndrome" where cognitive intent can no longer communicate with distal neuromuscular anatomy. Therefore, indirectly reconnecting motor plans to execution of its intended action could theoretically restore function. This concept has led to the development of bypass (ie, assistive) BMI, or ways to circumvent lesions to restore critical functions. 88 Such strategies 89, 90 are not necessarily designed to engender plasticity; however, it turns out that improved performance during long-term training with such BMIs is likely due in part to significant neuroplasticity. 73 Approaches to reanimating paralyzed extremities include functional electrical stimulation (FES) of distal musculature 10, 91, 92 and EES of distal spinal elements. [6] [7] [8] 88 FES involves the stimulation of electrodes in target muscles directed by signals decoded from a neural implant. So far, FES systems have enabled brain-controlled joint-specific movements of paralyzed limbs in 3 dimensions, and have assisted quadriplegic patients in feeding themselves. 10 Continuous EES, on the other hand, lowers the excitation threshold of intact distal neuronal circuitry such that any subclinical supraspinal connections can re-exert their influence and enable volitional control of the distal anatomy. 66, 67, 93 Demonstrations of such techniques have enabled both volitional and nonvolitional stepping movements, task-specific single-joint movements, and standing in patients with complete and chronic SCI [6] [7] [8] that in 1 case persisted after stimulation was ceased. 9 To help further develop control techniques for EES, FES, and proprioceptive stimulation modalities, ethical animal models for reversible paraplegia are also being developed.
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CELLULAR-MOLECULAR PRINCIPLES Cellular Signaling can Alter Axonal Sprouting
In the mature CNS, neurons do not spontaneously regenerate, and attempts at axonal regrowth generally fail due to a lack of appropriate extracellular guidance. [95] [96] [97] Therefore, altering intrinsic transcription factors and regeneration-associated genes may provide pharmacological solutions to enhance regrowth, guidance, and reinnervation. 50, [98] [99] [100] To date, several important targets have been identified, such as phosphatase and tensin homolog (PTEN) 101, 102 and Socs3. 103 Additionally, the protooncogene bcl-2 is known to play a key role in preventing cell death after injury. 104, 105 Also, growth and differentiation factor 10 and growth-associated protein 43 (GAP43) are known to promote axonal growth and are released in the subacute period after stroke in rat models. 31, 32 Moreover, use of the purine nucleoside inosine in animal models of SCI and stroke have been shown to restore GAP43 levels and improve behavioral outcomes. [27] [28] [29] 101, 106, 107 In addition, extrinsic factors like MAPs and proteoglycans can also prevent axonal regeneration, especially in glial scars formed after injury. [59] [60] [61] [62] However, recent evidence suggests that the glial scar itself may provide a necessary scaffolding for successful iatrogenically induced regeneration. 108 Removal or blockage of extracellular inhibitory factors alone has generally failed to achieve effective axonal regeneration. 109, 110 One exception has been neutralization of Nogo, a negative regulator of growth. 111 AntiNogo immunotherapies have successfully demonstrated increased sprouting associated with functional recovery in both rat 35, 112, 113 and primate 36 models of SCI and stroke. 13 Surgical intervention may be required to iatrogenically deliver therapies such as these to critical targets.
Inflammation is Complex and Important
While some components of inflammation cause tissue damage and apoptosis/necrosis, others promote phagocytosis, debris removal, cell survival, and axonal sprouting depending on timing after injury. 101, [114] [115] [116] [117] [118] Both oncomodulin, a macrophage-derived growth factor, and injury-induced cytokine release appear to play a role in inflammation-induced axonal regeneration. 116, 119, 120 Traditional anti-inflammatory therapies (eg, nonsteroidal antiinflammatory drugs) may stifle both helpful and harmful components of the immune response. 59, 115, 121 For example, when combined with PTEN deletion and elevation of cyclic adenosine monophosphate, intraocular inflammation has been shown to enable some retinal ganglion cells to regenerate injured axons from the eye to the brain and restore simple visual responses. 61 Therefore, therapeutic approaches might aim at balancing cellular phenotypes in the injury microenvironment, as microglia, macrophages, and astrocytes exhibit a spectrum of states that are under active investigation.
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Cellular Replacement may Work Through a Variety of Mechanisms
Rates and extent of recovery across patients with CNS injuries can vary widely. It is now recognized that some of this variability may be due to a host of cellular processes, such as (1) number and neuroplasticity of surviving neurons, synapses, and circuits; (2) extent of reorganization and neural innervation; (3) degree of dendritic arborization, synaptogenesis, and remyelination; (4) release of trophic factors; (5) activity of immune cells; and (6) generation of new neurons, glial, and endothelial cells from endogenous stem cells that integrate into injured neuronal networks. 124 Therefore, while traditional neural grafting has emphasized the role of neurons in reconstituting neural circuitry through synaptic connectivity, 125, 126 many new approaches emphasize a much broader range of cell sources and actions once grafted (Figure 4) . [127] [128] [129] [130] Though cellular transplantation has shown promise in animal models, 12, 131, 132 translation to neurological improvement in human studies has proven difficult as the underlying mechanisms of action remain poorly understood and unexpected toxicity has occurred. 133 In animal models of Huntington's disease 131 and ischemic stroke, direct injection of embryonic cells has been shown to improve deficits, 132 and a phase 1 clinical trial of human fetal brain-derived immortalized neural stem cells for stroke demonstrated safety with some suggestion of neurological improvement. 134 Recently, Kodoya et al 12 demonstrated robust CST regeneration and synapse formation caudal to an SCI after grafting homologous multipotent neural progenitor cells to the site of injury in rats. Similarly, cultured human neurons derived from an embryonal carcinoma cell line 135 were studied in an open-label phase 1 trial that showed improvement on the European Stroke Scale (ESS) and metabolism by fluorodeoxyglucose-positron emission tomography. 136 However, a subsequent phase 2 randomized study demonstrated no statistically significant difference in ESS or overall motor outcome, although improvement was seen on Fugl-Meyer Assessments and in cognitive function. 137 In addition to embryonic or carcinoma-derived stem cells, it is possible to genetically reprogram differentiated mature somatic cells, such as fibroblasts, into pluripotent stem cells that exhibit the morphology and growth properties of embryonic stem cells. 138 Use of autologous induced pluripotent stem cells has the potential to avoid immunosuppression and ethical issues associated with the use of human embryonic cells. An open-label phase 1/2a study of stereotactic injection of these cells into the area of a previous ischemic stroke demonstrated significant improvement in stroke scale and motor scores, leading to randomized controlled trials. 25 Thus, critical questions for future studies in addition to efficacy include defining viable cell sources, understanding safety concerns, delineating effects on endogenous cell populations, and understanding mechanisms of action for different cell lines. 
INTEGRATIVE PRINCIPLES Regeneration = Functional Restoration
Robust axonal regeneration and development of appropriate connectivity alone does not necessarily ensure restoration of function. 139 In 1 example, Bei et al 140 were able to induce adult mouse retinal axons to regrow and synapse in the superior colliculus; however, these connections did not restore visual function on their own-addition of a voltage-gated potassium channel blocker was required to enable the proper conduction of action potentials, as the newly regenerated axons were not properly myelinated. For more complex functions, targeted behavioral training will almost certainly need to accompany anatomic realignment to ensure establishment of the proper functional connectivity, 72 as not all plasticity is known to be beneficial (eg, spasticity, postinjury seizures, and pathological pain). Research groups remain heavily focused on both understanding the precise roles of different neuronal populations in repair, as well as crossing the bridge from structural to functional restoration.
Micro-and Macroscopic Interventions Might be Synergistic or Antagonistic, and Timing is Critical
While microscopic interventions can alter cell populations, improve cellular signaling, and induce axonal sprouting and synapse formation, macroscopic paradigms may strengthen and stabilize functional circuits to enhance performance. Therapy on each scale can affect the other in crucial ways. Wahl et al 13 perhaps most clearly demonstrated this principle when they injected an anti-NogoA antibody intrathecally into rats with large strokes, and then followed the injection with intensive taskspecific training ( Figure 5 ). When immunotherapy and training were combined simultaneously, greater axonal sprouting was seen, but fiber branching was chaotic and functional outcome was worse compared to no treatment (also seen by Maier et al 35 ). This demonstration illustrates both the distinction between simple regrowth and functional restoration, as well as the importance of timing between interventions on different scales to stabilize essential circuitry. In general, the principle of micro-and macroscopic interaction is only recently being rigorously explored. Such experiments can be difficult to design, execute, and interpret, as they require multidisciplinary expertise. However, achieving a better understanding and appreciation of such interplay appears to be critical for developing therapeutic strategies that hope to realize a positive clinical impact.
Conscious Engagement is Key for Long-Term Functional Improvement
One of the first studies to demonstrate the restoration of supraspinal control of gait in a rat model of SCI also demonstrated the importance of conscious engagement in long tract regrowth.
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In this study, all rats were trained with EES. However, the rats that were trained with passive treadmill rehabilitation achieved no restoration of volitional motor control, whereas the rats that were trained with goal-oriented tasks both regained volitional control of ambulation and showed evidence of functional long-tract regrowth. Additionally, in a human clinical trial of recovery after hemiparetic stroke, passively assisted robotic arm movements showed less improvement than unassisted, patientdirect movements. 141 Exactly how conscious agency relates to neuroanatomical principles of circuitry and guidance remains a mystery, but they are intimately connected. [142] [143] [144] From a clinical perspective, this implies that patients who suffer from disorders of consciousness (eg, comatose or vegetative patients) may need completely different therapeutic strategies which are much farther from being realized. It also suggests that experiments that have failed in vitro may still be viable therapies when integrated into a framework that includes conscious intent and goal-directed therapy, and therefore should not be explicitly excluded from clinical trial design. 4 
THE NEUROSURGEON'S ROLE IN CNS RESTORATION
Neurosurgeons have a unique opportunity to play a critical role in the advancement of therapeutic modalities aimed at functional CNS restoration. While most neurosurgeons interact with patients with neurological deficits from brain tumors, strokes, traumatic brain injury, or SCIs daily, they have limited tools to help such patients regain function after their condition has been stabilized. At this point in treatment, neurosurgeons generally take a back seat to other providers such as physical, occupational, and speech therapists. To advance the utility of interventions such as BMI, FES, EES, stem cell therapy, immunotherapy, pharmacotherapy, optogenetics, and gene therapy, collaborations between neurosurgeons, clinicians, therapists, basic scientists, funding agencies, and industry will be essential. Neurosurgeons have already played prominent roles in the BrainGate 10, 145 and the Northstar Neuroscience (Everest) trials, 19 and the progression of such techniques into the realm of CNS repair may provide opportunities for neurosurgeons to expand their capabilities in the care of these patients beyond just the implantation-stabilization phase. Furthermore, such BMI and cortical stimulation strategies will likely continue to play a large role in future macroscopic frameworks within which microscopic advancements will be tested.
The engagement of neurosurgeons early in the process of developing CNS repair strategies is essential not only because neurosurgeons maintain critical access to patients with CNS injuries and the ability to perform invasive CNS procedures, but neurosurgeons also have intimate clinical experience with the relationship between structural and functional CNS anatomy and its response to injury and intervention. Additionally, as any currently proposed therapy will need to navigate the tortuous pathway to FDA approval before realizing any large-scale implementation, neurosurgeons should be involved early to help stave off potential pitfalls of human translation and clinical trial design. Therefore, a basic understanding of the translational principles outlined in this manuscript and a sense for where therapeutic advances may be heading are necessary.
CONCLUSION
Despite numerous scientific advances, many patients continue to experience persistent functional deficits following SCI, stroke, and other CNS disorders. As explored in this review, new interventions are starting to provide hope for better outcomes, and strategic approaches that utilize both micro-and macroscopic interventions will be the most likely to have a broad clinical impact. While macroscopic (ie, systems-circuitry) techniques such as neural interfaces, FES, and EES have begun to demonstrate positive results in human patients, most microscopic (ie, cellular-molecular) therapies such as cellular treatments, immunotherapies, molecular interventions, and optogenetics remain in the in vitro or animal model stage and have encountered significant hurdles to clinically relevant translation. To make the leap, 3 strategic and harmonious integrative principles are important for future translational clinical trial design: (1) axonal regeneration does not by itself ensure functional restoration, (2) timing between cellular and systems-level (ie, behavioral) interventions is critical, and (3) conscious engagement plays a vital role in neurological restoration. Neurosurgeons will have the opportunity to play a variety of roles in the adaptation of such therapies into mainstream clinical practice, which can range from passive observers to expert technicians or intellectual leaders. Which role is played will largely depend on active and early engagement, an understanding of important translational neuroscience principles, and a willingness to collaborate and help facilitate clinical trial design.
Disclosures
Dr Krucoff 's time is supported by NINDS grant 5R25NS065731-08. Dr Turner's time is supported by VA grants I21 BX003023-01 and I21 RX002223, as well the NIH grant R21 AG051103-01. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.
